Preretinal Fibrosis

Categories: Eye diseases

Aliases & Classifications for Preretinal Fibrosis

MalaCards integrated aliases for Preretinal Fibrosis:

Name: Preretinal Fibrosis 12 15
Macular Puckering of Retina 12
Macular Retinal Puckering 12
Cellophane Maculopathy 12
Epiretinal Membrane 44


External Ids:

Disease Ontology 12 DOID:2006
ICD9CM 35 362.56
MeSH 44 D019773
SNOMED-CT 68 53428005 55991001
UMLS 73 C0339543

Summaries for Preretinal Fibrosis

MalaCards based summary : Preretinal Fibrosis, also known as macular puckering of retina, is related to vitreoretinopathy, neovascular inflammatory and macular holes. An important gene associated with Preretinal Fibrosis is GFAP (Glial Fibrillary Acidic Protein), and among its related pathways/superpathways are Osteoclast differentiation and EPHA forward signaling. The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include retina, eye and brain, and related phenotype is vision/eye.

Related Diseases for Preretinal Fibrosis

Diseases related to Preretinal Fibrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Related Disease Score Top Affiliating Genes
1 vitreoretinopathy, neovascular inflammatory 32.5 GFAP TGFB2
2 macular holes 31.1 TGFB2 VEGFA
3 retinal detachment 30.7 GFAP VEGFA
4 microvascular complications of diabetes 1 30.6 GFAP TGFB2 VEGFA
5 microvascular complications of diabetes 5 10.6
6 microvascular complications of diabetes 2 10.6
7 cataract 10.4
8 aniseikonia 10.4
9 vitreous detachment 10.3
10 combined hamartoma of the retina and retinal pigment epithelium 10.3
11 coats disease 10.2
12 retinitis 10.2
13 diabetic macular edema 10.2
14 retinitis pigmentosa 10.2
15 macular degeneration, age-related, 1 10.2
16 leber congenital amaurosis 4 10.2
17 kuhnt-junius degeneration 10.2
18 uveitis 10.2
19 eales disease 10.1
20 microcystic meningioma 10.0 GFAP VEGFA
21 angiomatous meningioma 10.0 GFAP VEGFA
22 pars planitis 10.0
23 stargardt disease 10.0
24 retinal vein occlusion 10.0
25 open-angle glaucoma 10.0
26 craniopharyngioma 10.0
27 chorioretinitis 10.0
28 refractive error 10.0
29 toxoplasmosis 10.0
30 supratentorial cancer 10.0 GFAP VEGFA
31 cerebrum cancer 10.0 GFAP VEGFA
32 hemangioblastoma 10.0 GFAP VEGFA
33 grade iii astrocytoma 10.0 GFAP VEGFA
34 neovascular glaucoma 10.0 TGFB2 VEGFA
35 central nervous system cancer 10.0 GFAP VEGFA
36 nervous system cancer 10.0 GFAP VEGFA
37 macular dystrophy, dominant cystoid 10.0
38 macular retinal edema 10.0
39 brain edema 9.9 GFAP VEGFA
40 corneal disease 9.9 TGFB2 VEGFA
41 regular astigmatism 9.9 DPT LCK
42 meningioma, familial 9.9 GFAP VEGFA
43 basal cell nevus syndrome 9.9
44 myotonic dystrophy 1 9.9
45 neurofibromatosis, type iv, of riccardi 9.9
46 strabismus 9.9
47 congenital heart defects, hamartomas of tongue, and polysyndactyly 9.9
48 gyrate atrophy of choroid and retina 9.9
49 insulin-like growth factor i 9.9
50 mucopolysaccharidosis, type ii 9.9

Graphical network of the top 20 diseases related to Preretinal Fibrosis:

Diseases related to Preretinal Fibrosis

Symptoms & Phenotypes for Preretinal Fibrosis

MGI Mouse Phenotypes related to Preretinal Fibrosis:

# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.02 DPT GFAP RLBP1 TGFB2 VEGFA

Drugs & Therapeutics for Preretinal Fibrosis

Drugs for Preretinal Fibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
Nepafenac Approved, Investigational Phase 4,Phase 3 78281-72-8 151075
Ranibizumab Approved Phase 4,Not Applicable 347396-82-1 459903
Verteporfin Approved, Investigational Phase 4 129497-78-5
Triazolam Approved, Investigational Phase 4 28911-01-5 5556
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
8 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Antirheumatic Agents Phase 4,Phase 3,Not Applicable
11 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Angiogenesis Inhibitors Phase 4,Phase 3,Not Applicable
23 Angiogenesis Modulating Agents Phase 4,Phase 3,Not Applicable
24 Immunologic Factors Phase 4,Not Applicable
25 Anesthetics Phase 4,Not Applicable
26 Analgesics, Non-Narcotic Phase 4,Phase 3,Not Applicable
27 Analgesics Phase 4,Phase 3,Not Applicable
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Not Applicable
29 Anti-Anxiety Agents Phase 4,Phase 3,Not Applicable
30 Psychotropic Drugs Phase 4,Phase 3,Not Applicable
31 Central Nervous System Depressants Phase 4,Phase 3,Not Applicable
32 Neurotransmitter Agents Phase 4,Phase 3,Not Applicable
33 Tranquilizing Agents Phase 4,Phase 3,Not Applicable
34 GABA Agents Phase 4,Phase 3,Not Applicable
35 Hypnotics and Sedatives Phase 4,Phase 3,Not Applicable
36 GABA Modulators Phase 4,Phase 3,Not Applicable
37 Photosensitizing Agents Phase 4
38 Dermatologic Agents Phase 4
39 Anesthetics, Intravenous Phase 4
40 Adjuvants, Anesthesia Phase 4
41 Anesthetics, General Phase 4
Colchicine Approved Phase 3 64-86-8 6167 2833
Triamcinolone Approved, Vet_approved Phase 3,Not Applicable 124-94-7 31307
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
Fluorouracil Approved Phase 3 51-21-8 3385
Dalteparin Approved Phase 3 9005-49-6
Bevacizumab Approved, Investigational Phase 3,Not Applicable 216974-75-3
Povidone Approved Phase 3,Not Applicable 9003-39-8
Iodine Approved, Investigational Phase 3,Not Applicable 7553-56-2 807
Povidone-iodine Approved Phase 3,Not Applicable 25655-41-8

Interventional clinical trials:

(show top 50) (show all 105)
# Name Status NCT ID Phase Drugs
1 Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery Completed NCT00818844 Phase 4 Nepafenac 0.1%
2 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study) Completed NCT01613716 Phase 4 Ozurdex
3 Cohort Study of the Clinical Course of Macular Diseases in Kagawa Recruiting NCT02321267 Phase 4 ranibizumab, aflibercept, pegaptanib, verteporphin
4 Oral Versus Intravenous Sedation for Ocular Procedures Recruiting NCT03246724 Phase 4 Triazolam;Midazolam;Microcrystalline Cellulose;Sodium chloride 0.9%
5 Day Regimes of CONbercept on CytokinEs of PDR Patients Undergoing Vitrectomy - Trial (CONCEPT) Recruiting NCT03506750 Phase 4 IVC
6 Brilliant Blue Versus Indocyanine Green Unknown status NCT01083004 Phase 3
7 Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery Unknown status NCT01820520 Phase 3 brilliant blue G
8 Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment Unknown status NCT00370201 Phase 3 colchicine
9 Surgical Management of Pseudophakic and Aphakic Retinal Detachment; a Randomized Clinical Trial Unknown status NCT00370279 Phase 3
10 Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR) Unknown status NCT00370760 Phase 3 oral colchicine, dexamethasone, low molecular weight heparin, 5-FU;placebo
11 Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy Completed NCT01627977 Phase 3
12 Ozurdex for Macular Edema Post Membrane Peeling Completed NCT01273727 Phase 2, Phase 3 Dexamethasone;dexamethasone
13 Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy Completed NCT01976923 Phase 3 Intravitreal bevacizumab
14 PGE2 Levels in Patient Treated With NSAIDs Completed NCT03597867 Phase 3 Dicloftil;Nevanac;Indom;Yellox
15 Pars Plana Vitrectomy for Diabetic Fibrovascular Proliferation With and Without Internal Limiting Membrane Peeling Unknown status NCT00556244 Phase 1, Phase 2
16 Study of OT-551 Eye Drops to Prevent or Delay Progression of Nuclear Cataracts Following Vitreous Removal Terminated NCT00333060 Phase 2 OT-551 ophthalmic solution
17 PK Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Vitrectomy Completed NCT02644694 Phase 1 Dexamethasone Phosphate Ophthalmic Solution
18 Change in Foveal Avascular Zone After Removal of Epiretinal Membrane and Internal Limiting Membrane Unknown status NCT01985490 Not Applicable
19 Outcomes of Vitrectomy Combined With Subtenon Triamcinolone Injection for the Idiopathic Epiretinal Membrane Unknown status NCT01630876 Not Applicable
20 Study of Retinal Sensitivity by Microperimetry During Epiretinal Membrane Surgery Unknown status NCT02084212 Not Applicable
21 A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Surgery for Epiretinal Membranes Unknown status NCT01701518 Not Applicable Ozurdex
22 Gene Expression in Patients With Epiretinal Membranes Unknown status NCT01946451
23 Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel Unknown status NCT00892619 Not Applicable
24 Comparison of Postoperative Aqueous Flare After 20G Versus 23G Pars Plana Vitrectomy Unknown status NCT01969929 Not Applicable
25 Double Endotamponade With Perfluorodecalin and Silicone Oil in Retinal Detachment Surgery. Unknown status NCT01959568 Not Applicable
26 Triple Therapy for Diffuse Diabetic Macular Edema Unknown status NCT01218750 Not Applicable
27 Optical Coherence Tomography - Rescan During Dissection of Macular Membranes Unknown status NCT02748421 Not Applicable
28 Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers Unknown status NCT02815176
29 MP3 (Microperimeter 3) Reproducibility in Healthy Subjects and Macular Patients Unknown status NCT02941406
30 Spectral-domain Optical Coherence Tomography of the Eye Unknown status NCT02614625
31 Causes of Visual Loss in Retinal Disease Unknown status NCT01613963 Immunosuppressive Agents
32 Microperimetry and Optical Coherence Tomography (OCT) in Idiopathic Epiretinal Membrane Completed NCT01481987 Not Applicable
33 Study of Impact of Air vs SF6 20% on Visual Acuity Improvement After Epiretinal Membrane Stripping Completed NCT02030262 Not Applicable
34 Retinal Layers and Visual Rehabilitation After Epiretinal Membrane Removal Completed NCT01474655 Not Applicable
35 Fundus Autofluorescence After Vitrectomy for Epiretinal Membrane Completed NCT02628158
36 Phacoemulsification and 25 Gauge (25G) Vitrectomy Versus Phacoemulsification Only in Idiopathic Epiretinal Membranes Completed NCT01771939 Not Applicable
37 Topical Use of Corticosteroid to Prevent Epiretinal Membrane Following Retinal Tear Completed NCT02412059 Not Applicable Prednisolone acetate
38 Surgical Removal of Idiopathic Epiretinal Membrane With and Without the Assistance of Indocyanine Green. Completed NCT00376857 Not Applicable Surgery with and without the aid of Indocyanine Green (ICG)
39 Mid-term Evaluation of Metamorphopsia in Epiretinal Membrane Surgery Completed NCT03045367
40 Prognostic Factors in Epiretinal Membrane Surgery Completed NCT02406430
41 Refractive Consequences of Epiretinal Membrane Surgery Completed NCT02413619 Not Applicable
42 Evaluation of the Cone Outer Segment Tips Line After Epiretinal Membrane Surgery Completed NCT01549249 Not Applicable
43 Trypan Blue Versus Brillant Blue for Epiretinal Membranes Completed NCT00757380 Not Applicable
44 Treatment of Epiretinal Membranes With Ranibizumab Completed NCT01238393 Not Applicable intravitreal ranibizumab
45 Prophylactic Ketorolac Post Epiretinal Membrane Surgery Completed NCT00974753 Not Applicable Ketorolac 0.5%
46 Inflammasomes in Cell Death in FTMH, ERM, and RRD Completed NCT03332758
47 "Cataract Surgery in Eyes With Epiretinal Membrane" Completed NCT03404323
48 Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes Completed NCT01846351
49 Change of Retinally-Induced Aniseikonia in Patients With Epiretinal Membrane After Vitrectomy Completed NCT01901406
50 UHR-OCT and HD-OCT for Preretinal Membranes: ICG Versus Membrane Blue Completed NCT00437593 Not Applicable

Search NIH Clinical Center for Preretinal Fibrosis

Cochrane evidence based reviews: epiretinal membrane

Genetic Tests for Preretinal Fibrosis

Anatomical Context for Preretinal Fibrosis

MalaCards organs/tissues related to Preretinal Fibrosis:

Retina, Eye, Brain

Publications for Preretinal Fibrosis

Articles related to Preretinal Fibrosis:

# Title Authors Year
Idiopathic preretinal fibrosis: a review of 237 cases. ( 1549286 )
Idiopathic preretinal fibrosis with concurrent cystoid macular edema. ( 3429756 )
Idiopathic preretinal fibrosis in young patient. ( 3842950 )

Variations for Preretinal Fibrosis

Expression for Preretinal Fibrosis

Search GEO for disease gene expression data for Preretinal Fibrosis.

Pathways for Preretinal Fibrosis

GO Terms for Preretinal Fibrosis

Cellular components related to Preretinal Fibrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell body GO:0044297 8.96 GFAP RLBP1
2 platelet alpha granule lumen GO:0031093 8.62 TGFB2 VEGFA

Biological processes related to Preretinal Fibrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet degranulation GO:0002576 9.43 TGFB2 VEGFA
2 kidney development GO:0001822 9.4 TGFB2 VEGFA
3 activation of protein kinase activity GO:0032147 9.37 TGFB2 VEGFA
4 response to wounding GO:0009611 9.32 GFAP TGFB2
5 hemopoiesis GO:0030097 9.26 LCK TGFB2
6 heart morphogenesis GO:0003007 9.16 TGFB2 VEGFA
7 positive regulation of cell division GO:0051781 8.96 TGFB2 VEGFA
8 collagen fibril organization GO:0030199 8.62 DPT TGFB2

Sources for Preretinal Fibrosis

9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
70 SNOMED-CT via Orphanet
72 Tocris
74 UMLS via Orphanet
Loading form....